As the global response to COVID-19 continues to move from a state of national lockdowns to the re-opening of societies, diagnostic assay developers are confronting two major challenges. Firstly, how to handle manufacturing volumes when level of demand is so uncertain. Secondly, where to invest in non-COVID diagnostics innovation and for which disease areas. Emmanuel Abate at Cytiva talks more about these two challenges.
Current Edition
Current Features
Subsection - Neurodegenerative Diseases
From Depression to Deep-Learning: Leveraging iPSC and AI Platforms for Evidence-Based Depression Treatment
Continue reading
IBI – International Biopharmaceutical Industry was established to fill in the void for effective marketing and communication between all stakeholders in the Life sciences sector globally.
Bio Pharmaceutical Media © 2026, All Rights Reserved – Powered by Teksyte